The inhibitor of Ca2+-dependent K+ channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB

Investigational New Drugs

Volumn 31, Issue 2, 2013, Pages 452-457

  Freise, Christian ^a   Ruehl, Martin ^a   Seehofer, Daniel ^a   Hoyer, Joachim ^b   Somasundaram, Rajan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

ESR1; HCC; IKCa; KCNN4; NF B; TRAM 34

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; ESR1 GENE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; ONCOGENE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; HUMANS; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; LIVER NEOPLASMS; PYRAZOLES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELA; TUMOR CELLS, CULTURED;

EID: 84879555211     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9879-6     Document Type: Article

References (32)

1. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557-2576
2. Villanueva A, et al. (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27(1):55-76
3. Cheng AL, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25-34
4. Llovet JM, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
5. Skryma RN, et al. (1997) Potassium conductance in the androgen-sensitive prostate cancer cell line, LNCaP: involvement in cell proliferation. Prostate 33(2):112-122
6. Parihar AS, et al. (2003) Effects of intermediate-conductance Ca2+-activated K+ channel modulators on human prostate cancer cell proliferation. Eur J Pharmacol 471(3):157-164
7. Nilius B, Wohlrab W (1992) Potassium channels and regulation of proliferation of human melanoma cells. J Physiol 445:537-548
8. Fraser SP, et al. (2003) Predominant expression of Kv1.3 voltage-gated K+ channel subunit in rat prostate cancer cell lines: electrophysiological, pharmacological and molecular characterisation. Pflugers Arch 446(5):559-571, Epub 2003 Jul 1
9. Ouadid-Ahidouch H, et al. (2000) KV1.1 K(+) channels identification in human breast carcinoma cells: involvement in cell proliferation. Biochem Biophys Res Commun 278(2):272-277
10. Jager H, et al. (2004) Blockage of intermediate-conductance Ca2+-activated K+ channels inhibit human pancreatic cancer cell growth in vitro. Mol Pharmacol 65(3):630-638
11. Farias LM, et al. (2004) Ether a go-go potassium channels as human cervical cancer markers. Cancer Res 64(19):6996-7001
12. Grgic I, et al. (2005) Selective blockade of the intermediate-conductance Ca2+-activated K+ channel suppresses proliferation of microvascular and macrovascular endothelial cells and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 25(4):704-709
13. Takahashi H, et al. (1998) Clotrimazole, an imidazole antimycotic, is a potent inhibitor of angiogenesis. Jpn J Cancer Res 89(4):445-451
14. Benzaquen LR, et al. (1995) Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat Med 1(6):534-540
15. Thapa D, et al. (2008) Clotrimazole ameliorates intestinal inflammation and abnormal angiogenesis by inhibiting interleukin-8 expression through a nuclear factor-kappaB-dependent manner. J Pharmacol Exp Ther 327(2):353-364, Epub 2008 Aug 26
16. Tettenborn D (1974) Toxicity of clotrimazole. Postgrad Med J 50(Suppl 1):17-20
17. Wulff H, et al. (2000) Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A 97(14):8151-8156
18. Fuchs BC, et al. (2008) Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 68(7):2391-2399
19. Freise C, et al. (2010) An active extract of Lindera obtusiloba inhibits adipogenesis via sustained Wnt signaling and exerts anti-inflammatory effects in the 3T3-L1 preadipocytes. J Nutr Biochem 21(12):1170-1177
20. Roy J, et al. (2009) The intermediate conductance Ca(2+)-activated K(+) channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. Br J Pharmacol 24:24
21. Hertlein E, et al. (2010) 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 116(1):45-53, Epub 2010 Mar 29
22. Leng AM, et al. (2012) The apoptotic effect and associated signaling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells. Cell Biol Int 14:14
23. Wang ZH, et al. (2007) Blockage of intermediate-conductance-Ca(2+)- activated K(+) channels inhibits progression of human endometrial cancer. Oncogene 26(35):5107-5114
24. Quast SA, et al. (2012) General sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMAC. PLoS 7(6):e39290, Epub 2012 Jun 18
25. Dalwadi H, et al. (2005) Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res 11(21):7674-7682
26. Calvisi DF, et al. (2008) Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis 29(8):1639-1647
27. Salminen A, Kaarniranta K (2009) Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-kappaB signaling. Cell Signal 22(4):573-577
28. Sun B, Karin M (2008) NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 27(48):6228-6244
29. Liu TZ, et al. (2000) Differentiation status modulates transcription factor NF-kappaB activity in unstimulated human hepatocellular carcinoma cell lines. Cancer Lett 151(1):49-56
30. Wu JM, et al. (2009) NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett 278(2):145-155
31. Zhai Y, et al. (2010) Loss of estrogen receptor 1 enhances cervical cancer invasion. Am J Pathol 177(2):884-895, Epub 2010 Jun 25
32. Kaushal V, et al. (2007) The Ca2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. J Neurosci 27(1):234-244